medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-20-26-32medalphabet-3917Research ArticleСтатьиКлючевые аспекты лабораторной диагностики поражения сердечно‑сосудистой системы при COVID‑19Key role of laboratory diagnostics of cardiovascular system injury in COVID‑19https://orcid.org/0000-0001-5369-987XТазинаС. Я.TazinaS. Ia.

Тазина Серафима Яковлевна - д.м.н., профессор кафедры ИПО.

Москва

Tazina Serafima Ya. - DM Sci (habil.), associate professor, professor at Therapy Dept of Professional Education Institute.

Moscow

tazin.re@yandex.ruАнтиповаИ. Ю.AntipovaI. Y.

Антипова Ирина Юрьевна - врач-терапевт, зав. отделением консультативного отделения.

Москва

Antipova Irina Iu. - general practitioner, head of Consulting Dept.

Moscow

https://orcid.org/0000-0003-1762-6934ФедороваТ. А.FedorovaT. A.

Фёдорова Татьяна Алексеевна - д.м.н., профессор кафедры терапии ИПО.

Москва

Fedorova Tatiana A. - DM Sci, professor at Therapy Dept of Professional Education Institute.

Moscow

ta-fedorova@mail.ruhttps://orcid.org/0000-0003-2592-6857РойтманА. П.RoytmanA. P.

Ройтман Александр Польевич - д.м.н., профессор кафедры клинической лабораторной диагностики с курсом клинической иммунологии РНМАНПО.

Москва

Roytman Alexandr P. - DM Sci (habil.), professor at Dept of Clinical Laboratory Diagnostics with a course in Clinical Immunology.

Moscow

a-roitman@mail.ruhttps://orcid.org/0000-0003-1404-4699БугровА. В.BugrovA. V.

Бугров Алексей Викторович - к.м.н., доцент кафедры клинической лабораторной диагностики с курсом клинической иммунологии РНМАНПО.

Москва

Bugrov Aleksey V. - PhD Med, associated professor at Dept of Clinical Laboratory Diagnostics with a course in Clinical Immunology.

Moscow

avb81@bk.ruФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationКлинический госпиталь ФКУЗ «Медико-санитарная часть Министерства внутренних дел России по г. Москве»РоссияClinical hospital “Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia in Moscow”Russian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy for Continuing Professional EducationRussian Federation202402112024020Серия «Современная лаборатория» (2)2632Copyright © Тазина С.Я., Антипова И.Ю., Федорова Т.А., Ройтман А.П., Бугров А.В., 20242024Тазина С.Я., Антипова И.Ю., Федорова Т.А., Ройтман А.П., Бугров А.В.Tazina S.I., Antipova I.Y., Fedorova T.A., Roytman A.P., Bugrov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3917

В данном обзоре литературы рассмотрены данные, характеризующие клиническое значение наиболее информативных лабораторных маркеров, позволяющих не только своевременно выявить патологию сердечно-сосудистой системы, но и оценить риск неблагоприятных исходов коронавирусной инфекции. К наиболее изученным относятся высокочувствительный Тропонин (hsTnI), Мозговой натрийуретический пептид (NT-proBNР), Д-димер. К перспективным лабораторным маркерам, требующим всестороннего изучения, можно отнести остеопонтин, стимулирующий фактор роста ST2, Галектоин-3 (Gal-3), копептин, эндотелин-1. При всем многообразии патологических состояний, которые сопровождаются увеличением концентраций указанных маркеров, их можно рассматривать как показатели, несомненно, заслуживающие пристального внимания при оценке больных COVID-19.

This literature review examines data characterizing the clinical significance of the most informative laboratory markers, which make it possible not only to promptly identify the pathology of the cardiovascular system, but also to assess the risk of adverse outcomes of coronavirus infection. The most studied markers are hsTnI, NT-proBNP, D-dimer. Promising laboratory markers that require comprehensive study include osteopontin, stimulating growth factor ST2, Gal-3, copeptin, endothelin-1. With all the variety of pathological conditions that are accompanied by an increase in the concentrations of these markers, they can be considered as indicators that undoubtedly deserve close attention when assessing patients with COVID-19.

высокочувствительный тропонин INT-proBNPД-димеростеопонинстимулирующий фактор роста ST2Gal-3копептинэндотелин-1COVID-19high sensitivity troponin INT-proBNPD-dimerosteoponinstimulating growth factor ST2Gal-3copeptinendothelin-1COVID-19Referenceshttps://covid19.who.int/https://covid19.who.int/Lu R, Zhao X, Li J, Niu P, Yang B et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–574. doi: 10.1016/S0140–6736 (20) 30251-8.Lu R, Zhao X, Li J, Niu P, Yang B et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–574. doi: 10.1016/S0140–6736 (20) 30251-8.Coopersmith CM, Antonelli M, Bauer SR et al. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med. 2021 Apr 1;49(4):598–622. doi:10.1097/CCM.0000000000004895. PMID: 33591008Coopersmith CM, Antonelli M, Bauer SR et al. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med. 2021 Apr 1;49(4):598–622. doi:10.1097/CCM.0000000000004895. PMID: 33591008Zizza A, Recchia V, Aloisi A, Guido M. Clinical features of COVID-19 and SARS epidemics. A literature review. J Prev Med Hyg. 2021 Apr 29;62(1): E 13-E 24. doi: 10.15167/2421–4248/jpmh2021.62.1.1680. PMID: 34322612; PMCID: PMC 8283653Zizza A, Recchia V, Aloisi A, Guido M. Clinical features of COVID-19 and SARS epidemics. A literature review. J Prev Med Hyg. 2021 Apr 29;62(1): E 13-E 24. doi: 10.15167/2421–4248/jpmh2021.62.1.1680. PMID: 34322612; PMCID: PMC 8283653Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus Disease 2019-Associated Coagulopathy. Mayo Clin Proc. 2021 Jan;96(1):203–217. doi: 10.1016/j.mayocp.2020.10.031. Epub 2020 Oct 31. PMID: 33413819; PMCID: PMC 7604017Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus Disease 2019-Associated Coagulopathy. Mayo Clin Proc. 2021 Jan;96(1):203–217. doi: 10.1016/j.mayocp.2020.10.031. Epub 2020 Oct 31. PMID: 33413819; PMCID: PMC 7604017Gattinoni L, Gattarello S, Steinberg I et al.. COVID-19 pneumonia: pathophysiology and management. Eur Respir Rev. 2021 Oct 20;30(162):210138. doi: 10.1183/16000617.0138–2021. PMID: 34670808; PMCID: PMC 8527244Gattinoni L, Gattarello S, Steinberg I et al.. COVID-19 pneumonia: pathophysiology and management. Eur Respir Rev. 2021 Oct 20;30(162):210138. doi: 10.1183/16000617.0138–2021. PMID: 34670808; PMCID: PMC 8527244Rahman S, Montero MTV, Rowe K et al. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021 May;14(5):601–621. doi: 10.1080/17512433.2021.1902303Rahman S, Montero MTV, Rowe K et al. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021 May;14(5):601–621. doi: 10.1080/17512433.2021.1902303Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020 Jul;108(1):17–41. doi: 10.1002/JLB.3COVR0520–272R.Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020 Jul;108(1):17–41. doi: 10.1002/JLB.3COVR0520–272R.Corman VM, Landt O, Kaiser M et al.. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020 Jan;25(3):2000045. doi: 10.2807/1560–7917.ES.2020.25.3.2000045.Corman VM, Landt O, Kaiser M et al.. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020 Jan;25(3):2000045. doi: 10.2807/1560–7917.ES.2020.25.3.2000045.Lai CKC, Lam W. Laboratory testing for the diagnosis of COVID-19. Biochem Biophys Res Commun. 2021 Jan 29;538:226–230. doi: 10.1016/j.bbrc.2020.10.069. Epub 2020 Oct 28. PMID: 33139015; PMCID: PMC 7598306.Lai CKC, Lam W. Laboratory testing for the diagnosis of COVID-19. Biochem Biophys Res Commun. 2021 Jan 29;538:226–230. doi: 10.1016/j.bbrc.2020.10.069. Epub 2020 Oct 28. PMID: 33139015; PMCID: PMC 7598306.Hoffmann M, Kleine-Weber H, Schroeder S et al.. SARS-CoV-2 Cell Entry Depends on ACE 2 and TMPRSS 2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. PMID: 32142651; PMCID: PMC 7102627Hoffmann M, Kleine-Weber H, Schroeder S et al.. SARS-CoV-2 Cell Entry Depends on ACE 2 and TMPRSS 2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. PMID: 32142651; PMCID: PMC 7102627КТ-картина коронавирусной болезни: результат по итогам работы COVID-центра на базе НМИЦ кардиологии. / Д. В. Устюжанин, М. Б. Белькинд, С. А. Гаман [и др.] // Российский электронный журнал лучевой диагностики.– 2020.– No 10(2).– С. 27–38.CT picture of coronavirus disease: the result of the work of the COVID center based on the NMIC of Cardiology. / D. V. Ustyuzhanin, M. B. Belkind, S. A. Gaman [et al.] // Russian Electronic Journal of Radiation Diagnostics.– 2020.– No. 10 (2).– P. 27–38. (In Russ.).Клинические рекомендации РФ 2023, Коронавирусная инфекция – COVID-19 (версия 18).Clinical guidelines of the Russian Federation 2023, Coronavirus infection – COVID-19 (version 18). (In Russ.).Shi S, Qin M, Shen B et al.. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802–810. doi: 10.1001/jamacardio.2020.0950. PMID: 32211816; PMCID: PMC 7097841Shi S, Qin M, Shen B et al.. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802–810. doi: 10.1001/jamacardio.2020.0950. PMID: 32211816; PMCID: PMC 7097841Grasselli G, Zangrillo A, Zanella A. et al.; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574–1581. doi: 10.1001/jama.2020.5394.Grasselli G, Zangrillo A, Zanella A. et al.; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574–1581. doi: 10.1001/jama.2020.5394.Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239–1242. doi: 10.1001/jama.2020.2648. PMID: 32091533.Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239–1242. doi: 10.1001/jama.2020.2648. PMID: 32091533.Lala A, Johnson KW, Januzzi JL et al.. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol. 2020 Aug 4;76(5):533–546. doi: 10.1016/j.jacc.2020.06.007.Lala A, Johnson KW, Januzzi JL et al.. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol. 2020 Aug 4;76(5):533–546. doi: 10.1016/j.jacc.2020.06.007.Semenzato L, Botton J, Drouin J et al.. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021 Sep;8:100158. doi: 10.1016/j.lanepe.2021.100158.Semenzato L, Botton J, Drouin J et al.. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021 Sep;8:100158. doi: 10.1016/j.lanepe.2021.100158.Sharifi Y, Payab M, Mohammadi-Vajari E et al.. Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review. J Diabetes Metab Disord. 2021 Jun 26;20(2):1743–1765. doi: 10.1007/s40200-021-00822-2. PMID: 34222055; PMCID: PMC 8233632.Sharifi Y, Payab M, Mohammadi-Vajari E et al.. Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review. J Diabetes Metab Disord. 2021 Jun 26;20(2):1743–1765. doi: 10.1007/s40200-021-00822-2. PMID: 34222055; PMCID: PMC 8233632.Zagidullin NS, Motloch LJ, Musin TI et al.. J-waves in acute COVID-19: A nov el disease characteristic and predictor of mortality? PLoS One. 2021 Oct 14;16(10): e0257982. doi: 10.1371/journal.pone.0257982. PMID: 34648510; PMCID: PMC 8516278Zagidullin NS, Motloch LJ, Musin TI et al.. J-waves in acute COVID-19: A nov el disease characteristic and predictor of mortality? PLoS One. 2021 Oct 14;16(10): e0257982. doi: 10.1371/journal.pone.0257982. PMID: 34648510; PMCID: PMC 8516278Ebashi S., Kodama A. A new protein factor promoting aggregation of tropomyosin// J. Biochem.– 1965.– Jul; 58(1).– Р. 107–108Ebashi S., Kodama A. A new protein factor promoting aggregation of tropomyosin// J. Biochem.– 1965.– Jul; 58(1).– Р. 107–108Greaser M. L., Gergely J. Purification and properties of the components from troponin// J. Biol. Chem.– 1973.– Mar 25;248(6).– Р. 2125–2133Greaser M. L., Gergely J. Purification and properties of the components from troponin// J. Biol. Chem.– 1973.– Mar 25;248(6).– Р. 2125–2133Thygesen K., Alpert J. S., Jaffe A. S. et al. ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction// Eur. Heart J.– 2012.– Vol. 33.– Р. 2551–2567Thygesen K., Alpert J. S., Jaffe A. S. et al. ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction// Eur. Heart J.– 2012.– Vol. 33.– Р. 2551–2567McEvoy J.W., Chen Y., Ndumele C. E. et.al. Six-year change in high-sensitivity cardiac troponin t and risk of subsequent coronary heart disease, heart failure, and death// JAMA Cardiol.– 2016.– Aug 1;1(5) – Р. 519–528McEvoy J.W., Chen Y., Ndumele C. E. et.al. Six-year change in high-sensitivity cardiac troponin t and risk of subsequent coronary heart disease, heart failure, and death// JAMA Cardiol.– 2016.– Aug 1;1(5) – Р. 519–528Masson S., Anand I., Favero C. et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials// Circulation.– 2012.– Jan 17;125(2) – Р. 280–288Masson S., Anand I., Favero C. et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials// Circulation.– 2012.– Jan 17;125(2) – Р. 280–288Wibowo A, Pranata R, Akbar MR, Purnomowati A, Martha JW. Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression. Int J Infect Dis. 2021 Apr;105:312–318. doi: 10.1016/j.ijid.2021.02.113.Wibowo A, Pranata R, Akbar MR, Purnomowati A, Martha JW. Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression. Int J Infect Dis. 2021 Apr;105:312–318. doi: 10.1016/j.ijid.2021.02.113.Ni W, Yang X, Liu J et al.. Acute Myocardial Injury at Hospital Admission Is Associated With All-Cause Mortality in COVID-19. J Am Coll Cardiol. 2020 Jul 7;76(1):124–125. doi: 10.1016/j.jacc.2020.05.007.Ni W, Yang X, Liu J et al.. Acute Myocardial Injury at Hospital Admission Is Associated With All-Cause Mortality in COVID-19. J Am Coll Cardiol. 2020 Jul 7;76(1):124–125. doi: 10.1016/j.jacc.2020.05.007.Gaze DC. Clinical utility of cardiac troponin measurement in COVID-19 infection. Ann Clin Biochem. 2020 May;57(3):202–205. doi: 10.1177/0004563220921888.Gaze DC. Clinical utility of cardiac troponin measurement in COVID-19 infection. Ann Clin Biochem. 2020 May;57(3):202–205. doi: 10.1177/0004563220921888.Zhou F, Yu T, Du R et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: 10.1016/S0140–6736(20)30566-3.Zhou F, Yu T, Du R et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: 10.1016/S0140–6736(20)30566-3.Santoso A, Pranata R, Wibowo A et al. . Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis. Am J Emerg Med. 2021 Jun;44:352–357. doi: 10.1016/j.ajem.2020.04.052.Santoso A, Pranata R, Wibowo A et al. . Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis. Am J Emerg Med. 2021 Jun;44:352–357. doi: 10.1016/j.ajem.2020.04.052.Lippi G., Lavie C. J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog. Cardiovasc. Dis. 2020;63(3):390–391Lippi G., Lavie C. J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog. Cardiovasc. Dis. 2020;63(3):390–391Zaninotto M, Mion MM, Padoan A, Babuin L, Plebani M. Cardiac troponin I in SARS-CoV-2-patients: The additional prognostic value of serial monitoring. Clin Chim Acta. 2020 Dec;511:75–80. doi: 10.1016/j.cca.2020.09.036.Zaninotto M, Mion MM, Padoan A, Babuin L, Plebani M. Cardiac troponin I in SARS-CoV-2-patients: The additional prognostic value of serial monitoring. Clin Chim Acta. 2020 Dec;511:75–80. doi: 10.1016/j.cca.2020.09.036.Kini A, Cao D, Nardin M et al.. Types of myocardial injury and mid-term outcomes in patients with COVID-19. Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):438–446. doi: 10.1093/ehjqcco/qcab053. PMID: 34458912Kini A, Cao D, Nardin M et al.. Types of myocardial injury and mid-term outcomes in patients with COVID-19. Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):438–446. doi: 10.1093/ehjqcco/qcab053. PMID: 34458912Laura De Michieli, Allan S Jaffe, Yader Sandoval. Use and Prognostic Implications of Cardiac Troponin in COVID-19. Cardiol Clin. 2022 Aug;40(3):287–300. doi: 10.1016/j.ccl.2022.03.005Laura De Michieli, Allan S Jaffe, Yader Sandoval. Use and Prognostic Implications of Cardiac Troponin in COVID-19. Cardiol Clin. 2022 Aug;40(3):287–300. doi: 10.1016/j.ccl.2022.03.005Клиническая лабораторная диагностика: в 2 т. Т. 1 / под ред. Профессора В. В. Долгова.– М.: ООО «Лабдиаг», 2017.– 464 с.Clinical laboratory diagnostics: in 2 volumes. Volume 1 / edited by Professor V. V. Dolgov.– M.: OOO Labdiag, 2017.– 464 p. (In Russ.).Zagidullin N, Motloch LJ, Gareeva D et al.. Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. J Clin Med. 2020 Feb 18;9(2):550. doi: 10.3390/jcm9020550. PMID: 32085400; PMCID: PMC 7073894Zagidullin N, Motloch LJ, Gareeva D et al.. Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. J Clin Med. 2020 Feb 18;9(2):550. doi: 10.3390/jcm9020550. PMID: 32085400; PMCID: PMC 7073894Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail. 2004 Mar 15;6(3):327–33. doi: 10.1016/j.ejheart.2004.01.006. PMID: 14987584Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail. 2004 Mar 15;6(3):327–33. doi: 10.1016/j.ejheart.2004.01.006. PMID: 14987584McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368.McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368.Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018 Jan 12;12:2. doi: 10.1186/s13036-017-0093-0. PMID: 29344085; PMCID: PMC 5766980Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018 Jan 12;12:2. doi: 10.1186/s13036-017-0093-0. PMID: 29344085; PMCID: PMC 5766980Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus Disease 2019-Associated Coagulopathy. Mayo Clin Proc. 2021 Jan;96(1):203–217. doi: 10.1016/j.mayocp.2020.10.031. Epub 2020 Oct 31. PMID: 33413819; PMCID: PMC 7604017Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus Disease 2019-Associated Coagulopathy. Mayo Clin Proc. 2021 Jan;96(1):203–217. doi: 10.1016/j.mayocp.2020.10.031. Epub 2020 Oct 31. PMID: 33413819; PMCID: PMC 7604017Zeng JH, Wu WB, Qu JX et al. . Cardiac manifestations of COVID-19 in Shenzhen, China. Infection. 2020 Dec;48(6):861–870. doi: 10.1007/s15010–020–01473-w. Epub 2020 Jul 28. PMID: 32725595; PMCID: PMC 7386384Zeng JH, Wu WB, Qu JX et al. . Cardiac manifestations of COVID-19 in Shenzhen, China. Infection. 2020 Dec;48(6):861–870. doi: 10.1007/s15010–020–01473-w. Epub 2020 Jul 28. PMID: 32725595; PMCID: PMC 7386384Jain SS, Liu Q, Raikhelkar J et al. . Indications for and Findings on Transthoracic Echocardiography in COVID-19. J Am Soc Echocardiogr. 2020 Oct;33(10):1278– 1284. doi: 10.1016/j.echo.2020.06.009.Jain SS, Liu Q, Raikhelkar J et al. . Indications for and Findings on Transthoracic Echocardiography in COVID-19. J Am Soc Echocardiogr. 2020 Oct;33(10):1278– 1284. doi: 10.1016/j.echo.2020.06.009.Guo T, Fan Y, Chen M et al.. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811–818. doi: 10.1001/jamacardio.2020.1017.Guo T, Fan Y, Chen M et al.. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811–818. doi: 10.1001/jamacardio.2020.1017.Caro-Codón J, Rey JR, Buño A et al. . Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur J Heart Fail. 2021 Mar;23(3):456–464. doi: 10.1002/ejhf.2095.Caro-Codón J, Rey JR, Buño A et al. . Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur J Heart Fail. 2021 Mar;23(3):456–464. doi: 10.1002/ejhf.2095.Lim W, Le Gal G, Bates SM et al.. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018 Nov 27;2(22):3226–3256. doi: 10.1182/bloodadvances.2018024828.Lim W, Le Gal G, Bates SM et al.. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018 Nov 27;2(22):3226–3256. doi: 10.1182/bloodadvances.2018024828.Zhang S, Liu Y, Wang X et al.. SARS-CoV-2 binds platelet ACE 2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020 Sep 4;13(1):120. doi: 10.1186/s13045-020-00954-7.Zhang S, Liu Y, Wang X et al.. SARS-CoV-2 binds platelet ACE 2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020 Sep 4;13(1):120. doi: 10.1186/s13045-020-00954-7.Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1131–1134. doi: 10.1515/cclm-2020–0198. PMID: 32119647Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1131–1134. doi: 10.1515/cclm-2020–0198. PMID: 32119647Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2245–2249. doi: 10.1016/j.dsx.2020.11.007.Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2245–2249. doi: 10.1016/j.dsx.2020.11.007.Zhou F, Yu T, Du R et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: 10.1016/S0140–6736 (20) 30566-3.Zhou F, Yu T, Du R et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: 10.1016/S0140–6736 (20) 30566-3.Zhang, L, Yan, X, Fan, Q. et al.. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemostasis 2020;18:1324–9. https://doi.org/10.1111/jth.14859Zhang, L, Yan, X, Fan, Q. et al.. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemostasis 2020;18:1324–9. https://doi.org/10.1111/jth.14859Poudel, A, Poudel, Y, Adhikari, A, Aryal, BB, Dangol, D, Bajracharya, T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One 2021;16: e0256744. https://doi.org/10.1371/journal.pone.0256744Poudel, A, Poudel, Y, Adhikari, A, Aryal, BB, Dangol, D, Bajracharya, T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One 2021;16: e0256744. https://doi.org/10.1371/journal.pone.0256744Jankowich M, Choudhary G. Endothelin-1 levels and cardiovascular events. Trends Cardiovasc Med. 2020 Jan;30(1):1–8. doi: 10.1016/j.tcm.2019.01.007.Jankowich M, Choudhary G. Endothelin-1 levels and cardiovascular events. Trends Cardiovasc Med. 2020 Jan;30(1):1–8. doi: 10.1016/j.tcm.2019.01.007.Chester A. H., Yacoub M. H. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2014;2014(2):62–78. Katherine M. R. M. Banecki and Kim A. Dora Endothelin-1 in Health and Disease. Int J Mol Sci. 2023 Jul; 24(14): 11295. doi: 10.3390/ijms241411295Chester A. H., Yacoub M. H. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2014;2014(2):62–78. Katherine M. R. M. Banecki and Kim A. Dora Endothelin-1 in Health and Disease. Int J Mol Sci. 2023 Jul; 24(14): 11295. doi: 10.3390/ijms241411295Abraham GR, Kuc RE, Althage M et al. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol. 2022 Jun;167:92–96. doi: 10.1016/j.yjmcc.2022.03.007.Abraham GR, Kuc RE, Althage M et al. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol. 2022 Jun;167:92–96. doi: 10.1016/j.yjmcc.2022.03.007.Bermejo-Martin J.F., García-Mateo N., Motos A. et al. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: A multicentre, prospective, cohort study. Lancet Microbe. 2023;4: E 431–E 441. doi: 10.1016/S2666–5247(23)00041-1Bermejo-Martin J.F., García-Mateo N., Motos A. et al. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: A multicentre, prospective, cohort study. Lancet Microbe. 2023;4: E 431–E 441. doi: 10.1016/S2666–5247(23)00041-1Bolignano D, Cabassi A, Fiaccadori E. et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014 Oct;52(10):1447–56. doi: 10.1515/cclm-2014–0379. PMID: 24940718Bolignano D, Cabassi A, Fiaccadori E. et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014 Oct;52(10):1447–56. doi: 10.1515/cclm-2014–0379. PMID: 24940718Pervez MO, Winther JA, Brynildsen J. et al. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers. 2018 Nov;23(7):654–663. doi: 10.1080/1354750X.2018.1474258Pervez MO, Winther JA, Brynildsen J. et al. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers. 2018 Nov;23(7):654–663. doi: 10.1080/1354750X.2018.1474258Hellenkamp K, Schwung J, Rossmann H, Kaeberich A, Wachter R, Hasenfuß G, Konstantinides S, Lankeit M. Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin. Eur Respir J. 2015 Dec;46(6):1701–10. doi: 10.1183/13993003.00857–2015.Hellenkamp K, Schwung J, Rossmann H, Kaeberich A, Wachter R, Hasenfuß G, Konstantinides S, Lankeit M. Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin. Eur Respir J. 2015 Dec;46(6):1701–10. doi: 10.1183/13993003.00857–2015.Baranowska B, Kochanowski J. Copeptin – a new diagnostic and prognostic biomarker in neurological and cardiovascular diseases. Neuro Endocrinol Lett. 2019 Dec;40(5):207–214. PMID: 32112544Baranowska B, Kochanowski J. Copeptin – a new diagnostic and prognostic biomarker in neurological and cardiovascular diseases. Neuro Endocrinol Lett. 2019 Dec;40(5):207–214. PMID: 32112544Lipinski MJ, Escárcega RO, D’Ascenzo F et al.. A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. Am J Cardiol. 2014 May 1;113(9):1581–91. doi: 10.1016/j.amjcard.2014.01.436Lipinski MJ, Escárcega RO, D’Ascenzo F et al.. A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. Am J Cardiol. 2014 May 1;113(9):1581–91. doi: 10.1016/j.amjcard.2014.01.436Жукова АВ, Арабидзе ГГ. Копептин как фактор риска краткосрочной летальности и развития повторных острых коронарных событий у пациентов с ОКС без подъема сегмента ST. Атеросклероз и дислипидемии. 2019; 3(36): 5–11. DOI: 10.34687/2219–8202.JAD.2019.03.0001Zhukova AV, Arabidze GG. Copeptin as a risk factor for short-term mortality and the development of recurrent acute coronary events in patients with ACS without ST segment elevation. Atherosclerosis and Dyslipidemia. 2019; 3(36): 5–11. (In Russ.). DOI: 10.34687/2219–8202.JAD.2019.03.0001Kaufmann CC, Ahmed A, Kassem M, et al. Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin. Clin Res Cardiol. 2022 Mar;111(3):343–354. doi: 10.1007/s00392-021-01970-4. Epub 2021 Nov 15. PMID: 34782921; PMCID: PMC 8592075Kaufmann CC, Ahmed A, Kassem M, et al. Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin. Clin Res Cardiol. 2022 Mar;111(3):343–354. doi: 10.1007/s00392-021-01970-4. Epub 2021 Nov 15. PMID: 34782921; PMCID: PMC 8592075Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018 Sep;59:17–24. doi: 10.1016/j.clinbiochem.2018.07.003. Epub 2018 Jul 10. PMID: 30003880Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018 Sep;59:17–24. doi: 10.1016/j.clinbiochem.2018.07.003. Epub 2018 Jul 10. PMID: 30003880Soejima H, Irie A, Fukunaga T, et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J. 2007 Dec;71(12):1879–84. doi: 10.1253/circj.71.1879. PMID: 18037740Soejima H, Irie A, Fukunaga T, et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J. 2007 Dec;71(12):1879–84. doi: 10.1253/circj.71.1879. PMID: 18037740Hayek SS, Roderburg C, Blakely P, et al. Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. J Clin Med. 2021 Aug 30;10(17):3907. doi: 10.3390/jcm10173907. PMID: 34501358; PMCID: PMC 8432103Hayek SS, Roderburg C, Blakely P, et al. Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. J Clin Med. 2021 Aug 30;10(17):3907. doi: 10.3390/jcm10173907. PMID: 34501358; PMCID: PMC 8432103Varım C, Demirci T, Cengiz H et al. Relationship between serum osteopontin levels and the severity of COVID-19 infection. Wien Klin Wochenschr. 2021 Apr;133(7–8):298–302. doi: 10.1007/s00508-020-01789-5.Varım C, Demirci T, Cengiz H et al. Relationship between serum osteopontin levels and the severity of COVID-19 infection. Wien Klin Wochenschr. 2021 Apr;133(7–8):298–302. doi: 10.1007/s00508-020-01789-5.Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016 Feb;106(2):145–52. doi: 10.5935/abc.20150151.Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016 Feb;106(2):145–52. doi: 10.5935/abc.20150151.Hur M, Kim H, Kim HJ, et al. Soluble ST2 has a prognostic role in patients with suspected sepsis. Ann Lab Med. 2015 Nov;35(6):570–7. doi: 10.3343/alm.2015.35.6.570. PMID: 26354344; PMCID: PMC 4579100Hur M, Kim H, Kim HJ, et al. Soluble ST2 has a prognostic role in patients with suspected sepsis. Ann Lab Med. 2015 Nov;35(6):570–7. doi: 10.3343/alm.2015.35.6.570. PMID: 26354344; PMCID: PMC 4579100Zhang J, Chen Z, Ma M, He Y. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Front Cardiovasc Med. 2022 Sep 26;9:924461. doi: 10.3389/fcvm.2022.924461. PMID: 36225958; PMCID: PMC 9548599Zhang J, Chen Z, Ma M, He Y. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Front Cardiovasc Med. 2022 Sep 26;9:924461. doi: 10.3389/fcvm.2022.924461. PMID: 36225958; PMCID: PMC 9548599Zeng Z, Hong XY, Li Y, Chen W, Ye G, Li Y, Luo Y. Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19. Biomark Med. 2020 Dec;14(17):1619–1629. doi: 10.2217/bmm-2020–0410. PMID: 33336592Zeng Z, Hong XY, Li Y, Chen W, Ye G, Li Y, Luo Y. Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19. Biomark Med. 2020 Dec;14(17):1619–1629. doi: 10.2217/bmm-2020–0410. PMID: 33336592Sánchez-Marteles M, Rubio-Gracia J, Peña-Fresneda N, et al. Early Measurement of Blood sST2 Is a Good Predictor of Death and Poor Outcomes in Patients Admitted for COVID-19 Infection. J Clin Med. 2021 Aug 11;10(16):3534. doi: 10.3390/jcm10163534.Sánchez-Marteles M, Rubio-Gracia J, Peña-Fresneda N, et al. Early Measurement of Blood sST2 Is a Good Predictor of Death and Poor Outcomes in Patients Admitted for COVID-19 Infection. J Clin Med. 2021 Aug 11;10(16):3534. doi: 10.3390/jcm10163534.Rubio-Gracia, J.; Sánchez-Marteles, M.; Garcés-Horna, V.et al. Multiple Approaches at Admission Based on Lung Ultrasound and Biomarkers Improves Risk Identification in COVID-19 Patients. J. Clin. Med. 2021, 10, 5478. https://doi.org/10.3390/jcm10235478Rubio-Gracia, J.; Sánchez-Marteles, M.; Garcés-Horna, V.et al. Multiple Approaches at Admission Based on Lung Ultrasound and Biomarkers Improves Risk Identification in COVID-19 Patients. J. Clin. Med. 2021, 10, 5478. https://doi.org/10.3390/jcm10235478Díaz-Alvarez L, Ortega E. The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens. Mediators Inflamm. 2017;2017:9247574. doi: 10.1155/2017/9247574.Díaz-Alvarez L, Ortega E. The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens. Mediators Inflamm. 2017;2017:9247574. doi: 10.1155/2017/9247574.Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020 Dec 3;21(23):9232. doi: 10.3390/ijms21239232. PMID: 33287402; PMCID: PMC 7731136Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020 Dec 3;21(23):9232. doi: 10.3390/ijms21239232. PMID: 33287402; PMCID: PMC 7731136Chow SL, Maisel AS, Anand I, et al. American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017 May 30;135(22): e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26. Erratum in: Circulation. 2017 Nov 7;136(19): e345. PMID: 28446515Chow SL, Maisel AS, Anand I, et al. American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017 May 30;135(22): e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26. Erratum in: Circulation. 2017 Nov 7;136(19): e345. PMID: 28446515Asleh R, Enriquez-Sarano M, Jaffe AS, Manemann SM, Weston SA, Jiang R, Roger VL. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. J Am Coll Cardiol. 2019 May 14;73(18):2286–2295. doi: 10.1016/j.jacc.2019.02.046. PMID: 31072572; PMCID: PMC 6512841Asleh R, Enriquez-Sarano M, Jaffe AS, Manemann SM, Weston SA, Jiang R, Roger VL. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. J Am Coll Cardiol. 2019 May 14;73(18):2286–2295. doi: 10.1016/j.jacc.2019.02.046. PMID: 31072572; PMCID: PMC 6512841Portacci A, Diaferia F, Santomasi C, Dragonieri S, Boniello E, Di Serio F, Carpagnano GE. Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure. Respir Med. 2021 Oct;187:106556. doi: 10.1016/j.rmed.2021.106556.Portacci A, Diaferia F, Santomasi C, Dragonieri S, Boniello E, Di Serio F, Carpagnano GE. Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure. Respir Med. 2021 Oct;187:106556. doi: 10.1016/j.rmed.2021.106556.Kazancioglu S, Yilmaz FM, Bastug A et al.. Assessment of Galectin-1, Galectin-3, and Prostaglandin E 2 Levels in Patients with COVID-19. Jpn J Infect Dis. 2021 Nov 22;74(6):530–536. doi: 10.7883/yoken.JJID.2021.020.Kazancioglu S, Yilmaz FM, Bastug A et al.. Assessment of Galectin-1, Galectin-3, and Prostaglandin E 2 Levels in Patients with COVID-19. Jpn J Infect Dis. 2021 Nov 22;74(6):530–536. doi: 10.7883/yoken.JJID.2021.020.Kuśnierz-Cabala B, Maziarz B, Dumnicka P, et al.. Diagnostic Significance of Serum Galectin-3 in Hospitalized Patients with COVID-19-A Preliminary Study. Biomolecules. 2021 Aug 1;11(8):1136. doi: 10.3390/biom11081136. PMID: 34439802; PMCID: PMC 8393726Kuśnierz-Cabala B, Maziarz B, Dumnicka P, et al.. Diagnostic Significance of Serum Galectin-3 in Hospitalized Patients with COVID-19-A Preliminary Study. Biomolecules. 2021 Aug 1;11(8):1136. doi: 10.3390/biom11081136. PMID: 34439802; PMCID: PMC 8393726

The authors declare that there are no conflicts of interest present.